AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
18 St. Jude Children's Research Hospital, Memphis, United States
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
20 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
ABSTRACT
Background
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with limited treatment options. The anti-apoptotic protein BCL-XL drives drug resistance, but responses to its inhibition are heterogeneous and depend on developmental stage. Here, we identify a hierarchy of therapeutic vulnerabilities and a metabolic basis for BCL-XL inhibitor (BCL-XLi) resistance, leading to a rational combination strategy.
Methods
We integrated DepMap CRISPR screening, BH3 profiling, and pharmacotyping across ALL cell lines and PDXs. T-ALL PDXs were stratified into developmental subtypes via CIBERSORTx based on a healthy human T-cell reference. BCL-XLi-resistant models were generated in vitro (Jurkat, MOLT-4) via incremental drug exposure and in vivo using navitoclax. Multi-omics (bulk/scRNA-seq, metabolomics, lipidomics) and Seahorse assays were applied. Synergy was evaluated in vitro, ex vivo across PDX subtypes, and in vivo in two PDX models using navitoclax plus Pegaspargase, with synergy quantified using Loewe model (SynergyFinder).
Results
Retrieving DepMap CRISPR dependency data, we observed that T-ALL cell lines exhibited stronger survival dependency on BCL-XL compared to B-ALL, with similar dependencies on BCL-2 and MCL-1. BH3 profiling confirmed that the HRK peptide (BCL-XL- selective) triggered cytochrome c release in 6 out of 7 T-ALL lines. Pharmacotyping revealed that T-ALL lines were highly sensitive to the BCL-XL inhibitors A1331852 and navitoclax, but resistant to venetoclax, in contrast to B-ALL. Pharmacotyping of 28 T-ALL and 29 B-ALL PDX samples showed that most T-ALL samples were sensitive to A1331852 but resistant to venetoclax. The BCL2L1/BCL2 gene expression ratio negatively correlated with drug sensitivity ratios (AUC_Navitoclax/Venetoclax and AUC_A1331852/Venetoclax).
Using CIBERSORTx to deconvolute bulk RNA-seq, we stratified T-ALL PDXs into “Stem-like”, “Progenitor-like”, and “Committed T” subtypes. The “Stem-like” subtype showed elevated BCL2 expression and activity, while the other two subtypes showed increased BCL2L1 expression and activity, validated in two independent T-ALL cohorts. Functional assays confirmed that “Stem-like” samples were most susceptible to BCL-2 inhibition, whereas “Progenitor-like” and “Committed T” subtypes preferentially responded to BCL-XL inhibition. GSEA revealed distinct metabolic signatures across subtypes, particularly involving α-ketoglutarate, glutamate, and lipid metabolism.
GSEA of BCL-XLi-resistant T-ALL cell lines showed downregulated OXPHOS, cholesterol homeostasis, and intrinsic apoptosis signaling in response to oxidative stress. Single cell RNA-seq of Navitoclax-resistant (Nav-R) and Navitoclax-untreated (Nav-U) PDX samples revealed 3 “Stem-like”, 3 “Progenitor-like”, 2 “Committed T” subclusters and a higher proportion of stem-like and G1-arrested cells in Nav-R. Pseudotime maturity correlated positively with OXPHOS and ETC but negatively with lipid metabolism. DEG analysis in Nav-R highlighted upregulation of fatty acid metabolism (ACADM, CPT1A) and downregulation of ETC (ATP5ME, COX6C, NDUFA3), with metabolic scoring confirming a shift from OXPHOS toward lipid utilization. Seahorse assays validated reduced OCR in resistant cell lines and PDX.
Untargeted metabolomics and lipidomics of Nav-R versus Nav-U showed increased long-chain saturated fatty acid β-oxidation, disrupted carnitine shuttle, and enhanced lipolysis. Given this adaptive rewiring, we combined BCL-XLi with asparaginase (ASNase, Pegaspargase). Combination further suppressed OCR beyond single agents in PDX and Jurkat. Metabolomic profiling of Jurkat revealed significant reductions in glutamate, glutamine, aspartate, asparagine, triacylglycerols and free fatty acids after combination, with decreased free carnitine and increased acyl-carnitine conjugates. Combination (navitoclax/ASNase and A1331852/ASNase) demonstrated strong synergy across cell lines and diverse PDX subtypes. In two T-ALL PDX models, treatment with navitoclax plus ASNase significantly delayed leukemia progression and prolonged survival compared with either monotherapy or vehicle (P<0.05).
Conclusions
Our findings establish that BCL-XLi resistance in T-ALL is developmentally regulated and metabolically driven by a switch to fatty acid oxidation, which creates a vulnerability exploitable by ASNase, providing a mechanistic rationale for this promising combination strategy.